Administrative Supplement to MD Anderson Cancer Center Prostate Cancer SPORE

项目总结/摘要 通过此申请，德克萨斯大学MD安德森癌症中心寻求资金， 前列腺癌孢子本申请是根据多个主要研究者计划（MPI）提交的 由首席研究员Christopher J. Logothetis博士和Timothy C.汤普森，他们被公认为 MD安德森前列腺癌孢子在国际上对前列腺癌的研究， 稳定和动态的基础设施，以满足和成功地解决特定的 减少前列腺癌患者痛苦和死亡率的挑战。我们继续在我们的 进行新颖，创新的临床试验的能力，并相信我们进行的新研究项目 转化研究团队将在临床实践中取得实质性进展和有意义的变化。在 目前的建议，我们定义我们的转化研究的挑战和目标为（1）定量定义 前列腺癌的风险，以消除过度治疗的低风险前列腺癌，（2）开发新的 克服去势抵抗性前列腺癌（CRPC）对可用药物的抗性的治疗方法 治疗，和（3）开发CRPC和难治性疾病的新的替代策略。我们 将通过识别和测试新的预测和预后来实现这些转化研究目标 生物标志物，以确定是否需要治疗的早期前列腺癌患者，发展和 测试CRPC的新型免疫疗法，开发和测试克服骨分泌的新方法， 介导的骨转移对治疗的抗性，并开发和测试导入联合治疗， 最大化CRPC的DNA损伤反应靶向治疗。我们将通过四项研究来实现我们的目标 项目（包括一个人口科学研究项目）、3个支助核心（行政、生物统计和 生物信息学，生物标本和病理学），一个动态的发展研究计划， 有效的职业提升计划。我们乐观地认为，我们的研究工作将有助于 通过基础研究，降低这种毁灭性疾病的发病率、发病率和死亡率 临床实践中的发现。

PROJECT SUMMARY/ABSTRACT Through this application, The University of Texas MD Anderson Cancer Center seeks funding for renewal of its Prostate Cancer SPORE. This application is submitted under the Multiple Principal Investigator plan (MPI) by Principal Investigators Drs. Christopher J. Logothetis and Timothy C. Thompson, who are recognized internationally for their research in prostate cancer, The MD Anderson Prostate Cancer SPORE has created a stable and dynamic infrastructure for translational research to meet and successfully address specific challenges in reducing suffering and mortality rates for men with prostate cancer. We continue to build on our capacity to conduct novel, innovative clinical trials and believe that new research projects conducted by our translational research team will yield substantial progress and meaningful changes in clinical practice. In the current proposal, we define our translational research challenges and goals as (1) quantitative definition of prostate cancer risk to eliminate overtreatment of low-risk prostate cancer, (2) development of novel therapeutic approaches to overcoming resistance of castration-resistant prostate cancer (CRPC) to available therapies, and (3) development of novel alternative strategies for CRPC and treatment-refractory disease. We will achieve these translational research goals by identifying and testing novel predictive and prognostic biomarkers to determine the need for therapy in patients with early-stage prostate cancer, developing and testing novel immunotherapy for CRPC, developing and testing a novel approach to overcoming osteocrine- mediated resistance of bone metastasis to therapy, and developing and testing lead-in combination therapy to maximize DNA damage response-targeted therapy for CRPC. We will accomplish our goals via 4 research projects (including one population science research project), 3 support cores (Administrative, Biostatistics and Bioinformatics, and Biospecimen and Pathology), a dynamic Developmental Research Program, and an effective Career Enhancement Program. We are optimistic that our research efforts will contribute to reductions in the incidence, morbidity, and mortality of this devastating disease by translating basic research findings into clinical practice.